Precigen says FDA grants platform technology designation for AdenoVerse immunotherapy platform

• FDA granted platform technology designation to Precigen’s AdenoVerse immunotherapy platform.
• Status could speed development of new AdenoVerse-based programs by leveraging PAPZIMEOS manufacturing and preclinical data in future filings.
• AdenoVerse underpins PAPZIMEOS, an FDA-approved treatment for recurrent respiratory papillomatosis cleared in August 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609210700PR_NEWS_USPR_____NY52199) on September 21, 2026, and is solely responsible for the information contained therein.